Elimination of onchocerciasis in Africa by 2025: an ambitious target requires ambitious interventions.


Journal

Infectious diseases of poverty
ISSN: 2049-9957
Titre abrégé: Infect Dis Poverty
Pays: England
ID NLM: 101606645

Informations de publication

Date de publication:
03 Oct 2019
Historique:
received: 10 05 2019
accepted: 04 09 2019
entrez: 4 10 2019
pubmed: 4 10 2019
medline: 1 1 2020
Statut: epublish

Résumé

To achieve the elimination of onchocerciasis transmission in all African countries will entail enormous challenges, as has been highlighted by the active discussion around onchocerciasis intervention strategies and evaluation procedures in this journal.Serological thresholds for onchocerciasis elimination, adapted for the African setting, need to be established. The Onchocerciasis Technical Advisory Subgroup of the World Health Organization is currently developing improved guidelines to allow country elimination committees to make evidence-based decisions. Importantly, onchocerciasis-related morbidity should not be forgotten when debating elimination prospects. A morbidity management and disease prevention (MMDP) strategy similar to that for lymphatic filariasis will need to be developed. This will require collaboration between the onchocerciasis elimination program, the community and other partners including primary health and mental health programs.In order to reach the goal of onchocerciasis elimination in most African countries by 2025, we should prioritize community participation and advocate for tailored interventions which are scientifically proven to be effective, but currently considered to be too expensive.

Identifiants

pubmed: 31578157
doi: 10.1186/s40249-019-0593-x
pii: 10.1186/s40249-019-0593-x
pmc: PMC6775645
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

83

Subventions

Organisme : European Research Council
ID : 671055
Pays : International
Organisme : Bill&Melinda Gates Foundation, Neglected Tropical Diseaeses Modeling Consortium
ID : OPP1184344

Références

Community Eye Health. 2018;31(101):25
pubmed: 29915468
Infect Dis Poverty. 2016 Jun 27;5(1):66
pubmed: 27349645
Wkly Epidemiol Rec. 2011 Dec 16;86(51-52):581-5
pubmed: 22191103
Clin Infect Dis. 2018 Jun 1;66(suppl_4):S267-S274
pubmed: 29860291
J Infect Dis. 2019 Jun 14;:null
pubmed: 31201416
Infect Dis Poverty. 2019 Jul 15;8(1):52
pubmed: 31303175
Infect Dis Poverty. 2019 Jul 15;8(1):62
pubmed: 31303174
Trends Parasitol. 2018 Mar;34(3):208-216
pubmed: 29288080
Infect Dis Poverty. 2018 Jul 3;7(1):63
pubmed: 29966535
Infect Dis Poverty. 2019 Jul 15;8(1):50
pubmed: 31303176
Curr Opin Infect Dis. 2000 Oct;13(5):457-464
pubmed: 11964814
Int J Infect Dis. 2019 Feb;79:187-194
pubmed: 30711145
Infect Dis Poverty. 2018 Dec 3;7(1):114
pubmed: 30501640
Seizure. 2018 Dec;63:93-101
pubmed: 30468964
Infect Dis Poverty. 2018 Jun 20;7(1):64
pubmed: 29921319

Auteurs

Robert Colebunders (R)

Global health Institute, University of Antwerp, Antwerp, Belgium. robert.colebunders@uantwerpen.be.

Wilma A Stolk (WA)

Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Joseph Nelson Siewe Fodjo (JN)

Global health Institute, University of Antwerp, Antwerp, Belgium.

Charles D Mackenzie (CD)

Task force for Global Health, Decatur, Georgia, USA.

Adrian Hopkins (A)

Neglected and Disabling Diseases of Poverty Consultant, Gravesend, Kent, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH